Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
This article was originally published in The Gray Sheet
Executive Summary
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company